These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 11187421)
1. Nonhypoglycemic effects of thiazolidinediones. Parulkar AA; Pendergrass ML; Granda-Ayala R; Lee TR; Fonseca VA Ann Intern Med; 2001 Jan; 134(1):61-71. PubMed ID: 11187421 [TBL] [Abstract][Full Text] [Related]
2. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Diamant M; Heine RJ Drugs; 2003; 63(13):1373-405. PubMed ID: 12825962 [TBL] [Abstract][Full Text] [Related]
3. Metabolic and additional vascular effects of thiazolidinediones. Martens FM; Visseren FL; Lemay J; de Koning EJ; Rabelink TJ Drugs; 2002; 62(10):1463-80. PubMed ID: 12093315 [TBL] [Abstract][Full Text] [Related]
4. Management of diabetes mellitus and insulin resistance in patients with cardiovascular disease. Fonseca VA Am J Cardiol; 2003 Aug; 92(4A):50J-60J. PubMed ID: 12957327 [TBL] [Abstract][Full Text] [Related]
5. Insulin resistance and its treatment by thiazolidinediones. Lebovitz HE; Banerji MA Recent Prog Horm Res; 2001; 56():265-94. PubMed ID: 11237217 [TBL] [Abstract][Full Text] [Related]
6. Management of co-existing diabetes mellitus and dyslipidemia: defining the role of thiazolidinediones. Florkowski CM Am J Cardiovasc Drugs; 2002; 2(1):15-21. PubMed ID: 14727995 [TBL] [Abstract][Full Text] [Related]
7. Hepatotoxicity with thiazolidinediones: is it a class effect? Scheen AJ Drug Saf; 2001; 24(12):873-88. PubMed ID: 11735645 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Lebovitz HE; Kreider M; Freed MI Diabetes Care; 2002 May; 25(5):815-21. PubMed ID: 11978674 [TBL] [Abstract][Full Text] [Related]
10. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus. Defronzo RA; Mehta RJ; Schnure JJ Hosp Pract (1995); 2013 Apr; 41(2):132-47. PubMed ID: 23680744 [TBL] [Abstract][Full Text] [Related]
11. Thiazolidinediones and liver toxicity. Scheen AJ Diabetes Metab; 2001 Jun; 27(3):305-13. PubMed ID: 11431595 [TBL] [Abstract][Full Text] [Related]
12. Effects of the thiazolidinediones on cardiovascular risk factors. Gilling L; Suwattee P; DeSouza C; Asnani S; Fonseca V Am J Cardiovasc Drugs; 2002; 2(3):149-56. PubMed ID: 14727977 [TBL] [Abstract][Full Text] [Related]
13. [Effects of thiazolidinediones on dyslipidemia in patients with type 2 diabetes. Are all equally vasoprotective?]. Haberbosch W Herz; 2007 Feb; 32(1):51-7. PubMed ID: 17323035 [TBL] [Abstract][Full Text] [Related]
14. [Cardiovascular effects of the thiazolidinedione troglitazone]. Yamada K; Kuzuya H; Nakano T Nihon Rinsho; 2000 Feb; 58(2):435-9. PubMed ID: 10707572 [TBL] [Abstract][Full Text] [Related]
20. [Diabetes therapy related to etiology. Indications, uses and side effects of new insulin sensitizers]. Ludvik B MMW Fortschr Med; 2000 Jul; 142(28-29):27-8. PubMed ID: 10959156 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]